Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.

Rebecca Jane Moor,Kate Roberts,Robert Mason,Ben Gunawan,Sophie Feng,Jun-Hee Hong,Mitchell Von Itzstein,Brett Hughes,Zarnie Lwin,Vikram Kumar Jain,Kieron James Bigby,Mary Azer,Jasotha Sanmugarajah,Kenneth J. OByrne

Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.

2018

Rebecca Jane Moor
Kate Roberts
Robert Mason
Ben Gunawan
Sophie Feng
Jun-Hee Hong
Mitchell Von Itzstein
Brett Hughes
Zarnie Lwin
Vikram Kumar Jain
Kieron James Bigby
Mary Azer
Jasotha Sanmugarajah
Kenneth J. OByrne

9067Background: Immune checkpoint inhibitors are routinely used in Non Small Cell Lung Cancer (NSCLC) patients following progression on first-line therapy. Immune-related Adverse Events (IrAEs) hav...

Keywords:

Nivolumab
Immune system
Retrospective cohort study
Lung cancer
Physical therapy
Adverse effect
Medicine
Oncology
immune checkpoint inhibitors
Internal medicine
non small cell
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations